Federal Pharmaceuticals (03933) receives US$13.5 million in milestone payments from Novo Nordisk for UBT251 exclusive license agreement

Zhitongcaijing · 2d ago

Zhitong Finance App News, Federal Pharmaceuticals (03933) announced that on July 15, 2026, Federal Biotech has received US$13.5 million in global phase I clinical milestone payments from Novo Nordisk for UBT251 injections for overweight or obesity indications (after deducting Danish withholding tax).

Under an exclusive license agreement and subject to its terms and conditions, Federal Biotech is eligible to receive potential milestone payments of up to $1.8 billion, subject to reaching certain development and sales milestones, as well as tiered sales commissions based on the region's annual net sales.